← Back to Search

Nonsteroidal Anti-inflammatory Drug

162mg daily aspirin dose for Prophylaxis of Preeclampsia

Phase 4
Waitlist Available
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BMI at enrollment >/= 30
plan for ASA for preeclampsia prevention
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average for 10 months
Awards & highlights

Study Summary

This study is evaluating whether a higher dose of aspirin may help prevent preeclampsia in high risk women.

Eligible Conditions
  • Prophylaxis of Preeclampsia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average for 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average for 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Diagnosis of preeclampsia
Secondary outcome measures
Incidence of aspirin resistance based on incomplete inhibition of TBx2

Trial Design

2Treatment groups
Active Control
Group I: 81 mg daily aspirin doseActive Control1 Intervention
obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
Group II: 162mg daily aspirin doseActive Control1 Intervention
obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor
821 Previous Clinical Trials
500,935 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~32 spots leftby Mar 2025